Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05204186

Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence

Clinician and the multidisciplinary team meeting in oncologic urology (MMO) play a key-role in the decision making. An unexplained surgeon attributable variance, probably linked to the subjective "eyeball test" effect, was identified as a strongest factor underlying non-compliance with guide line recommendations in the management of bladder cancer. So high-quality studies that identify barriers and modulators (such as comorbidities) of provider-level adoption of guidelines and how comorbidities are associated in making therapeutic choice and their impact in bladder cancer specific survival and overall survival, are crucial. To identify patients at high risk of early death, and to improve specific guideline for treatment might be decisive.

In order to assess survival, where mortality events compete, it will be more appropriate to compute a Cumulative Incidence Function (namely CIF). The investigators will compare outcomes across patient populations to obtain information to improve clinical decision-making. Such learning will be done through the use of neural networks or by applying population-based approaches, such as Genetic Algorithms (GA), Ant Colony Systems (ACS) and Particle Swarm Optimization (PSO), using as a four-stage based approach.

First, the investigators propose a "pretopology space" in order to study a dynamic phenomenon. Second, the investigators recall that the K-means approach remains one of the most used approaches for classifying a set of elements (patients / persons / others) into K (disjunctive) clusters. Third, the investigators propose a learning pretopology space for enhancing the clustering. Such an approach can be assimilated in spirit to one applied with high success on deep learning. Fourth and last, the investigators propose a reactive method that is able to include some new elements or remove some contained elements

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years and older
  • Patient treated by radical cystectomy for bladder cancer

Exclusion criteria

  • Computed tomography/magnetic resonance evidence of distant metastases.

Treatment and study plan

Primary outcomes

  1. bladder cancer therapeutic choice as determined with this Artificial Intelligence predictive method

    Time frame: 90 days

    After retrieving associated comorbidities, any Grade 3, and over, Clavien-Dindo grading system complication rate (30dC and 90dC), information on primary treatment for bladder cancer (urothelial type and pT1 to pT4), outcome, time and cause of death, by our technician (from medical files of specific support centers), the primary objectives will be to model incorporation of comorbidities in making therapeutic choice, to improve care for patients with bladder cancer and specific guideline for treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Fabien SAINT, Pr

CONTACT

[email protected]

03 22 45 59 52

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Official study title

Evaluation of the Impact of COMORBIDities on Morbidity and Mortality After Radical Cystectomy for Cancer Using a Predictive Method With Artificial Intelligence

Acronym: COMORBID-AI

Important dates

Study start
2021
Primary completion
2028
Study completion
2028
First posted
Jan 24, 2022
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.